Evidence map›Paper›PMID 35729650›Full record

ReviewCell & bioscience2022

Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star.

Qun Chen, Jiajia Li, Peng Shen, Hao Yuan, Jie Yin, Wanli Ge, Wujun Wang, Guangbin Chen, Taoyue Yang, Bin Xiao and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Cell & bioscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. American journal of cancer research · 2023
    Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Qun Chen *Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiajia Li *Affiliated Hospital of Yangzhou University, Yangzhou, China.
Peng Shen *Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hao YuanPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie YinPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wanli GePancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wujun WangNanjing Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Guangbin ChenPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Taoyue YangPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Bin XiaoPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi MiaoPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zipeng LuPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pengfei WuPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. wupengfei@njmu.edu.cn.
Kuirong JiangPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. jiangkuirong@njmu.edu.cn.ORCID http://orcid.org/0000-0002-2849-5450
Jiangsu Province Hospital · CNNanjing University of Chinese Medicine · CNNorthern Jiangsu People's Hospital · CN

Funding

National Natural Science Foundation of China 81672449National Natural Science Foundation of China 81871980National Natural Science Foundation of China 82103280
6 · The paper itself

Abstract

Pancreatic cancer (PC) is a highly malignant solid tumor with insidious onset and easy early metastasis. Despite tremendous efforts devoted to research in this field, the mechanisms underlying PC tumorigenesis and progression remain unclear. Additionally, robust biomarkers and satisfactory therapeutic strategies for clinical use in PC patients are still lacking. Circular RNAs (circRNAs) are a new type of non-coding RNA originating from precursor messenger RNAs, with a covalent continuous closed-loop structure, strong stability and high specificity. Accumulating evidence suggests that circRNAs may participate in PC development and progression. Abnormal expression of circRNAs in PC is considered a vital factor that affects tumor cell proliferation, migration, invasion, apoptosis, angiogenesis and drug resistance. In this review of relevant articles published in recent years, we describe the basic knowledge concerning circRNAs, including their classification, biogenesis, functions and research approaches. Moreover, the biological roles and clinical significance of circRNAs related to PC are discussed. Finally, we note the questions remaining from recent studies and anticipate that further investigations will address these gaps in knowledge in this field. In conclusion, we expect to provide insights into circRNAs as potential targets for specific PC diagnosis and treatment in the future.

Indexed as

BiomarkerCancer diagnosis and therapyCircRNAsPancreatic cancer

Identifiers

PMID35729650
PMCPMC9210669
OpenAlexW4283211121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.